ATE253558T1 - Azazykloalkanone serin-protease-hemmer - Google Patents

Azazykloalkanone serin-protease-hemmer

Info

Publication number: ATE253558T1
Authority: AT; Austria
Prior art keywords: sup; sub; methylene; azazykloal; cannone
Prior art date: 1999-09-13

Application number

AT00963388T

Other languages

English (en)

Inventor

Scott C Miller

N S Nchez Juan Jose Marug

Kristin D Haslow

Jonathan P Hall

Original Assignee

Dimensional Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-13

Filing date

2000-09-13

Publication date

2003-11-15

2000-09-13 Application filed by Dimensional Pharm Inc filed Critical Dimensional Pharm Inc

2003-11-15 Application granted granted Critical

2003-11-15 Publication of ATE253558T1 publication Critical patent/ATE253558T1/de

Links

239000003001 serine protease inhibitor Substances 0.000 title 1
-1 biphenylyl Chemical group 0.000 abstract 4
229940123583 Factor Xa inhibitor Drugs 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
239000005977 Ethylene Chemical group 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 abstract 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 abstract 1
125000005518 carboxamido group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000002883 imidazolyl group Chemical group 0.000 abstract 1
125000001041 indolyl group Chemical group 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 abstract 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
125000004076 pyridyl group Chemical group 0.000 abstract 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1
230000001732 thrombotic effect Effects 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pyrrole Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

AT00963388T 1999-09-13 2000-09-13 Azazykloalkanone serin-protease-hemmer ATE253558T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15323699P	1999-09-13	1999-09-13
PCT/US2000/025006 WO2001019795A1 (en)	1999-09-13	2000-09-13	Azacycloalkanone serine protease inhibitors

Publications (1)

Publication Number	Publication Date
ATE253558T1 true ATE253558T1 (de)	2003-11-15

Family

ID=22546339

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00963388T ATE253558T1 (de)	1999-09-13	2000-09-13	Azazykloalkanone serin-protease-hemmer

Country Status (20)

Country	Link
US (2)	US6469029B1 (de)
EP (1)	EP1212300B1 (de)
JP (1)	JP2003509409A (de)
KR (1)	KR20020027639A (de)
CN (1)	CN1373755A (de)
AT (1)	ATE253558T1 (de)
AU (1)	AU7480800A (de)
BR (1)	BR0013926A (de)
CA (1)	CA2384247A1 (de)
DE (1)	DE60006407T2 (de)
DK (1)	DK1212300T3 (de)
ES (1)	ES2209987T3 (de)
HK (1)	HK1050005A1 (de)
IL (1)	IL148358A0 (de)
MX (1)	MXPA02002657A (de)
NO (1)	NO322753B1 (de)
NZ (1)	NZ517603A (de)
PL (1)	PL354265A1 (de)
PT (1)	PT1212300E (de)
WO (1)	WO2001019795A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI288745B (en)	2000-04-05	2007-10-21	Daiichi Seiyaku Co	Ethylenediamine derivatives
HUP0304058A2 (hu)	2001-01-30	2004-04-28	Bristol-Myers Squibb Company	Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
WO2002094787A1 (en) *	2001-05-23	2002-11-28	Ucb, S.A.	2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
WO2003000657A1 (en)	2001-06-20	2003-01-03	Daiichi Pharmaceutical Co., Ltd.	Diamine derivatives
GB0127568D0 (en)	2001-11-16	2002-01-09	Glaxo Group Ltd	Chemical compounds
CN100513398C (zh)	2002-12-03	2009-07-15	Axys药物公司	作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物
US20070191306A1 (en) *	2005-08-17	2007-08-16	Bristol-Myers Squibb Company	FACTOR Xa INHIBITOR FORMULATION AND METHOD
WO2009096198A1 (ja) *	2008-02-01	2009-08-06	Pharma Ip Limited Liability Intermediary Corporations	新規ビアリール誘導体
CN103910688B (zh) *	2013-01-04	2016-05-25	陈春麟	2-丙基-4-氯喹唑啉衍生物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4727064A (en)	1984-04-25	1988-02-23	The United States Of America As Represented By The Department Of Health And Human Services	Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en)	1985-03-15	1985-04-17	Janssen Pharmaceutica Nv	Derivatives of y-cyclodextrin
US5002935A (en)	1987-12-30	1991-03-26	University Of Florida	Improvements in redox systems for brain-targeted drug delivery
US5385885A (en)	1988-01-15	1995-01-31	Gasic; Gregory P.	Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide
DE4121947A1 (de)	1991-07-03	1993-01-07	Basf Ag	2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung
CA2075154A1 (en) *	1991-08-06	1993-02-07	Neelakantan Balasubramanian	Peptide aldehydes as antithrombotic agents
WO1994020535A1 (en)	1992-12-11	1994-09-15	Corvas International, Inc.	ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR
US5703208A (en)	1994-06-17	1997-12-30	Corvas International, Inc.	3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
JPH10503176A (ja) *	1994-06-17	1998-03-24	コーバスインターナショナル，インコーポレイテッド	酵素インヒビターとしての３−アミノ−２−オキソ−１−ピペリジン酢酸誘導体
JPH11508558A (ja) *	1995-06-27	1999-07-27	メルクエンドカンパニーインコーポレーテッド	ピリジノントロンビン阻害剤
JPH09165370A (ja)	1995-10-13	1997-06-24	Fuji Yakuhin Kogyo Kk	ラクタム誘導体およびその塩
CA2246256A1 (en)	1996-02-13	1997-08-21	Akzo Nobel Nv	Serine protease inhibitors
JP2000512616A (ja)	1996-02-22	2000-09-26	メルクエンドカンパニーインコーポレーテッド	ピリジノントロンビンインヒビター
ES2273365T3 (es)	1996-03-29	2007-05-01	Ortho-Mcneil Pharmaceutical, Inc.	Amidinohidrazonas utiles como inhibidores de proteasa.
WO1998016523A2 (en) *	1996-10-11	1998-04-23	Cor Therapeutics, Inc.	Selective factor xa inhibitors
WO1999007731A1 (en)	1997-08-11	1999-02-18	Cor Therapeutics, Inc.	SELECTIVE FACTOR Xa INHIBITORS
CA2300478A1 (en)	1997-08-11	1999-02-18	Cor Therapeutics, Inc.	Selective factor xa inhibitors
US6037356A (en)	1997-11-26	2000-03-14	3-Dimensional Pharmaceuticals, Inc.	Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors

2000
- 2000-09-13 AT AT00963388T patent/ATE253558T1/de not_active IP Right Cessation
- 2000-09-13 ES ES00963388T patent/ES2209987T3/es not_active Expired - Lifetime
- 2000-09-13 DK DK00963388T patent/DK1212300T3/da active
- 2000-09-13 BR BR0013926-2A patent/BR0013926A/pt not_active Application Discontinuation
- 2000-09-13 PL PL00354265A patent/PL354265A1/xx not_active Application Discontinuation
- 2000-09-13 PT PT00963388T patent/PT1212300E/pt unknown
- 2000-09-13 US US09/661,327 patent/US6469029B1/en not_active Expired - Lifetime
- 2000-09-13 JP JP2001523375A patent/JP2003509409A/ja active Pending
- 2000-09-13 WO PCT/US2000/025006 patent/WO2001019795A1/en not_active Ceased
- 2000-09-13 CN CN00812827A patent/CN1373755A/zh active Pending
- 2000-09-13 MX MXPA02002657A patent/MXPA02002657A/es unknown
- 2000-09-13 EP EP00963388A patent/EP1212300B1/de not_active Expired - Lifetime
- 2000-09-13 AU AU74808/00A patent/AU7480800A/en not_active Abandoned
- 2000-09-13 DE DE60006407T patent/DE60006407T2/de not_active Expired - Fee Related
- 2000-09-13 HK HK03102217.0A patent/HK1050005A1/zh unknown
- 2000-09-13 IL IL14835800A patent/IL148358A0/xx unknown
- 2000-09-13 NZ NZ517603A patent/NZ517603A/en unknown
- 2000-09-13 CA CA002384247A patent/CA2384247A1/en not_active Abandoned
- 2000-09-13 KR KR1020027003241A patent/KR20020027639A/ko not_active Withdrawn
2002
- 2002-03-12 NO NO20021224A patent/NO322753B1/no unknown
- 2002-09-16 US US10/243,938 patent/US6962942B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
IL148358A0 (en)	2002-09-12
CA2384247A1 (en)	2001-03-22
WO2001019795A1 (en)	2001-03-22
NZ517603A (en)	2003-09-26
NO20021224L (no)	2002-05-13
DE60006407T2 (de)	2004-09-09
US6962942B2 (en)	2005-11-08
CN1373755A (zh)	2002-10-09
NO322753B1 (no)	2006-12-04
KR20020027639A (ko)	2002-04-13
HK1050005A1 (zh)	2003-06-06
US6469029B1 (en)	2002-10-22
NO20021224D0 (no)	2002-03-12
JP2003509409A (ja)	2003-03-11
BR0013926A (pt)	2002-07-23
PT1212300E (pt)	2004-03-31
AU7480800A (en)	2001-04-17
DE60006407D1 (de)	2003-12-11
MXPA02002657A (es)	2002-10-28
ES2209987T3 (es)	2004-07-01
DK1212300T3 (da)	2004-03-15
EP1212300B1 (de)	2003-11-05
PL354265A1 (en)	2003-12-29
EP1212300A1 (de)	2002-06-12
US20030109517A1 (en)	2003-06-12

Legal Events

Date

Code

Title

Description

2004-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1212300

Country of ref document: EP

2009-06-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
EA200300306A1 (ru)	2003-08-28	Спиропиримидин-2,4,6-трионовые ингибиторы металлопротеиназы
DE69924135D1 (de)	2005-04-14	Heterozyklische kalium-kanal inhibitoren
MY127894A (en)	2006-12-29	Renin inhibitors
WO2001019828A3 (en)	2001-10-04	Kinase inhibitors as therapeutic agents
HN2002000028A (es)	2002-04-22	Pirimidinas inhibidoras de metaloproteinasas
ATE309999T1 (de)	2005-12-15	Blutplättchen-adp-rezeptor-inhibitoren
TR200001279T2 (tr)	2000-10-23	Poli (ADP-riboz) polimeraz ("PARP") inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler.
NO20020214D0 (no)	2002-01-15	Substituerte oksozaheterocyklylforbindelser
ECSP045104A (es)	2004-06-28	Ligandos de los receptores de los cannabinoides
ATE361748T1 (de)	2007-06-15	1-(4-sulfamylphenyl)-3-trifluormethyl-5-aryl-2- pyrazoline als cyclooxygenase-2 inhibitoren
BR0013926A (pt)	2002-07-23	Inibidores de serina protease de azacicloalcanona
IL179607A0 (en)	2007-05-15	Indoles useful in the treatment of inflammation
DE602004014484D1 (de)	2008-07-31	Verwendung von azetidincarboxamidderivaten in therapie
DK1458393T3 (da)	2008-10-13	Substituerede diketopiperaziner som oxytocinantagonister
ATE296827T1 (de)	2005-06-15	Heteropolycyclische inhibitoren
SE9902267D0 (sv)	1999-06-16	New compounds
ATE203905T1 (de)	2001-08-15	Thrombin inhibitor
EA200000204A1 (ru)	2000-10-30	Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
AU2002339158A1 (en)	2003-06-10	2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
DK1049670T3 (da)	2002-11-11	Azetidincarboxamidderivater til behandling af CNS-lidelser
WO2003064378A3 (de)	2004-01-08	Verbindungen, die faktor xa-aktivität
DE69811734D1 (de)	2003-04-03	Carboxylsäure substituierte heterocyclische verbindungen als metalloproteinase inhibitoren
ATE265453T1 (de)	2004-05-15	Diketopiperazinderivate als thrombininhibitoren
MX9709386A (es)	1998-10-31	Derivados del arilsulfonilaminobenceno y el uso de los mismos como inhibidores del factor xa.